

Jusmedico Advokatanpartsselskab

Teknikerbyen 5, 2., 2830 Virum

CVR no. 30 72 81 06

Annual report 2024

Approved at the Company's annual general meeting on 27 June 2025

Chair of the meeting:

.....
Jan Bjerrum Bach

Contents

Statement by the Executive Board	2
Independent auditor's report	3
Management's review	5
Company details	5
Financial statements 1 January - 31 December	8
Income statement	8
Balance sheet	9
Statement of changes in equity	11
Notes to the financial statements	12

Statement by the Executive Board

Today, the Executive Board has discussed and approved the annual report of Jusmedico Advokatanpartsselskab for the financial year 1 January - 31 December 2024.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024.

Further, in my opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

It is proposed to the annual general meeting that the financial statements for 2025 should not be audited.

I recommend that the annual report be approved at the annual general meeting.

Virum, 27 June 2025
Executive Board:

.....
Jan Bjerrum Bach
Managing Director, CEO

The general meeting has decided that the financial statements for the coming financial year will not be audited.

Independent auditor's report

To the shareholder of Jusmedico Advokatanpartsselskab

Opinion

We have audited the financial statements of Jusmedico Advokatanpartsselskab for the financial year 1 January - 31 December 2024, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2024 and of the results of the Company's operations for the financial year 1 January - 31 December 2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

Independent auditor's report

- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 27 June 2025
EY Godkendt Revisionspartnerselskab
CVR no. 30 70 02 28

Robert Christensen
State Authorised Public Accountant
mne16653

Management's review

Company details

Name	Jusmedico Advokatanpartsselskab
Address, Postal code, City	Teknikerbyen 5, 2., 2830 Virum
CVR no.	30 72 81 06
Established	10 May 2004
Registered office	Rudersdal
Financial year	1 January - 31 December
Telephone	+45 45 48 44 48
Executive Board	Jan Bjerrum Bach, Managing Director, CEO
Auditors	EY Godkendt Revisionspartnerselskab Dirch Passers Allé 36, P.O. Box 250, 2000 Frederiksberg, Denmark

Management's review

Business review

Jusmedico Law Firm Ltd. Advokatanpartsselskab ("Jusmedico"), is a specialist law firm providing legal services to the biotech, pharmaceutical, medical device and dentistry industries, life science investors and to suppliers and service providers thereto. The working areas of Jusmedico include research & development, pre-clinical test and clinical trial, data protection, production & supply, labelling & packaging, licensing, co-promotion & co-marketing agreements, agent and distribution agreements, as well as advertising & promotion advice. In addition Jusmedico renders legal advice to life science clients on third party liability insurance programs providing cover for clinical testing of investigational medicinal products and D&O programs.

Jusmedico, which was established in May 2004, was transformed into a private limited company on 1 January 2007. In 2018 a holding structure was established enabling partners to join the operational part of the group. Preparing to retire within a limited period of time the holding company has, effective as from 1 January 2024, been merged with Jusmedico on 21 May 2025.

During 2024 Jusmedico has continued its co-operation with the members of its Advisory Board established in 2007. The Advisory Board comprises 9 professionals, including 7 specialists within the fields of research, patenting, clinical development, insurance, regulatory service, quality management, start-up tax planning and accounting. These areas of expertise are especially relevant to Jusmedico's client portfolio, which comprises clients operating on a private commercial basis as well as on a non-profit public basis. The chairman of the Jusmedico Advisory Board is counselor at law Brian Marshall Hand, Esq., Jusmedico Law Group, New York, who is also in charge of Jusmedico's representative office in New York, USA, see <https://jusmedicolaw.com/>

Internationally Jusmedico is a founding member of the BioLawEurope Alliance comprising a network of independent European law firms, see <http://www.jusmedico.com/biolaweuropa>, and individual attorneys licensed in one or more EU-, EFTA-, UK- and/or CH jurisdictions, providing legal services focusing on the same legal disciplines as Jusmedico. In 2024 Jusmedico has assumed the role as secretary and treasurer of the BioLawEurope Alliance, which in May 2024 held its 10th Annual Meeting in Copenhagen, Denmark. For the 2025/2026 term Jusmedico has designated a board member of the BioLawEurope Alliance.



From 2015 - 2024 the BioLawEurope Alliance was headquartered in Copenhagen. Effective as from 1 January 2025, the headquarter has moved to Zürich, Switzerland.

In addition to activities via the BioLawEurope Alliance and referrals from the representative office in New York, Jusmedico is co-operating nationally and internationally with other law firms, which on an ad hoc basis may be involved in assignments falling outside Jusmedico's core competence areas.

The BioLawEurope Alliance and the Advisory Board initiatives enable co-operation across the boundaries of individual professions and enable Jusmedico involving all relevant professionals in larger and/or long term client projects.

Jusmedico's marketing activities primarily comprise participation in the BioLawEurope Alliance, homepage maintenance and professional networking domestically and internationally. Generally the international focus has been instrumental to Jusmedico having been and being retained by clients from especially CH, the US and Asia.

Jusmedico has continued to render services to new life science sector start-ups, including to assist them as their projects develop. However, Jusmedico has experienced a general interest from investors and clients in having their biotech and pharma sector portfolios rebalanced to include investments in other sectors, especially in the financial services sector, which has caused a corresponding reduction of pharma and biotech investments.

Management's review

In 2025 Jusmedico will, hence, be focusing on both life science as well as financial service sector activities envisaged to be holding potential for exits within a 5 year horizon. Hence, Jusmedico's allocation of staff to life science related activities, incl. med tech, has and will be reduced. In spite hereof and in spite of the climate crisis, which has caused Jusmedico's travel policy to exclude flying, and Russia's continued aggression and war campaigns in Ukraine, the 2024 turnover has been satisfactory.



*Legal 100 - 2025 Awards
Biotech Sector Law Firm of the Year, Denmark*

Considering the refocusing of the business, Jusmedico continues receiving acknowledgements from stakeholders in the life sciences sector such as the Legal 100 - 2025 Award above.

Management is satisfied with the Company's revenues amounting to MDKK 1.6 in 2024, against MDKK 1.5 in 2023, which numbers do not reflect that Jusmedico - obviously within the scope of the ethical rules - has accepted shareholdings as compensation in several cases.

Management proposes to the general meeting that dividends are paid for 2024 to the shareholders in the amount of TDKK 107,400.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

Financial statements 1 January - 31 December

Income statement

Note	DKK	2024	2023
	Revenue	1,648,276	1,518,157
	Other operating income	32,067	41,918
	Other external expenses	-628,125	-593,448
	Gross profit	1,052,218	966,627
2	Staff costs	-603,223	-255,043
	Amortisation/depreciation and impairment of intangible assets and property, plant and equipment	-52,666	-52,666
	Profit before net financials	396,329	658,918
	Financial income	256,794	383,297
	Financial expenses	-343,573	-10,569
	Profit before tax	309,550	1,031,646
3	Tax for the year	-72,753	-231,264
	Profit for the year	236,797	800,382
	Recommended appropriation of profit		
	Proposed dividend recognised under equity	107,400	122,000
	Retained earnings	129,397	678,382
		236,797	800,382

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	<u>2024</u>	<u>2023</u>
	ASSETS		
	Fixed assets		
4	Property, plant and equipment		
	Fixtures and fittings, other plant and equipment	17,557	70,223
		<u>17,557</u>	<u>70,223</u>
5	Investments		
	Other receivables	3,186,814	3,681,446
	Deposits, investments	32,708	31,438
		<u>3,219,522</u>	<u>3,712,884</u>
	Total fixed assets	<u>3,237,079</u>	<u>3,783,107</u>
	Non-fixed assets		
	Receivables		
	Trade receivables	1,022,322	530,406
	Corporation tax receivable	35,095	0
	Other receivables	116,490	424,718
	Prepayments	62,306	81,591
		<u>1,236,213</u>	<u>1,036,715</u>
	Securities and investments		
	Other securities and investments	1,724,943	1,581,138
		<u>1,724,943</u>	<u>1,581,138</u>
6	Cash	1,005,440	717,098
	Total non-fixed assets	<u>3,966,596</u>	<u>3,334,951</u>
	TOTAL ASSETS	<u><u>7,203,675</u></u>	<u><u>7,118,058</u></u>

Financial statements 1 January - 31 December

Balance sheet

Note	DKK	2024	2023
	EQUITY AND LIABILITIES		
	Equity		
	Share capital	500,000	500,000
	Retained earnings	6,332,317	6,202,920
	Dividend proposed	107,400	122,000
	Total equity	<u>6,939,717</u>	<u>6,824,920</u>
	Provisions		
	Deferred tax	2,905	13,847
	Total provisions	<u>2,905</u>	<u>13,847</u>
	Liabilities other than provisions		
	Current liabilities other than provisions		
	Trade payables	61,781	61,743
	Corporation tax payable	63	80,262
	Payables to shareholders and management	0	10,254
	Other payables	199,209	127,032
		<u>261,053</u>	<u>279,291</u>
	Total liabilities other than provisions	<u>261,053</u>	<u>279,291</u>
	TOTAL EQUITY AND LIABILITIES	<u><u>7,203,675</u></u>	<u><u>7,118,058</u></u>

- 1 Accounting policies
- 8 Contractual obligations and contingencies, etc.
- 9 Security and collateral

Financial statements 1 January - 31 December

Statement of changes in equity

DKK	Share capital	Retained earnings	Dividend proposed	Total
Equity at 1 January 2023	500,000	5,524,538	117,800	6,142,338
Transfer through appropriation of profit	0	678,382	122,000	800,382
Dividend distributed	0	0	-117,800	-117,800
Equity at 1 January 2024	500,000	6,202,920	122,000	6,824,920
Transfer through appropriation of profit	0	129,397	107,400	236,797
Dividend distributed	0	0	-122,000	-122,000
Equity at 31 December 2024	500,000	6,332,317	107,400	6,939,717

The Company has carried out an intra-group business combination with Jusmedico Holdings, Advokatanpartsselskab applying the uniting-of-interests method. The equity as of 1 January 2023 is therefore combined figures of the two entities.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies

The annual report of Jusmedico Advokatanpartsselskab for 2024 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Reporting currency

The financial statements are presented in Danish kroner (DKK).

Intra-group business combinations

The Company has carried out an intra-group business combination applying the uniting-of-interests method. Subsequently, the comparative figures have been restated as if the entities had been combined as from the earliest accounting period included in the financial statements.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

Income statement

Revenue

The Company has chosen IAS 11/IAS 18 as interpretation for revenue recognition.

Income from the rendering of services is recognised as revenue as the services are rendered. Accordingly, revenue corresponds to the market value of the services rendered during the year (percentage-of-completion method).

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

Other operating income

Other operating income comprise items secondary to the principal activities of the Company, including rental income from the temporary lease out of production facilities, compensation, government grants, refund of wages and salaries, gains on the disposal of intangible assets and property, plant and equipment, etc. Compensation and grants are recognised when there is reasonable assurance that the entity will comply with the conditions attaching to them and the grants will be received.

Other external expenses

Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to sale, advertising, administration, premises, bad debts, etc.

Staff costs

Staff costs include wages and salaries as well as other social security contributions, etc.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Depreciation

The item comprises depreciation of property, plant and equipment.

The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows:

Fixtures and fittings, other plant and equipment	3-5 years
Leasehold improvements	10 years

Financial income and expenses

Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

Balance sheet

Property, plant and equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.

Investments

Investments comprise deposits related to the Company's rentals. Investments are measured at cost.

Impairment of fixed assets

The carrying amount of property, plant and equipment is assessed for impairment on an annual basis.

Impairment tests are conducted on assets or groups of assets when there is evidence of impairment. The carrying amount of impaired assets is reduced to the higher of the net selling price and the value in use (recoverable amount).

The recoverable amount is the higher of the net selling price of an asset and its value in use. The value in use is calculated as the present value of the expected net cash flows from the use of the asset or the group of assets and the expected net cash flows from the disposal of the asset or the group of assets after the end of the useful life.

Previously recognised impairment losses are reversed when the reason for recognition no longer exists. Impairment losses on goodwill are not reversed.

Receivables

The Company has chosen IAS 39 as interpretation for impairment write-down of financial receivables.

Receivables are measured at amortised cost.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Prepayments

Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.

Securities and investments

Securities and investments consisting in listed shares and bonds are measured at fair value (market price) at the balance sheet date. Investments not admitted to trading on an active market are measured at cost.

Cash

Cash comprise bank deposits, which are readily convertible into cash and subject only to minor risks of changes in value. Cash also comprise client funds deposited in the company. Client funds entrusted to the Company (klienttilsvar) are offset against cash.

Equity

Proposed dividends

Dividend proposed for the year is recognised as a liability once adopted at the annual general meeting (declaration date). Dividends expected to be distributed for the financial year are presented as a separate item under "Equity".

Provisions

Provisions comprise anticipated expenses relating to deferred tax liabilities. Provisions are recognised when the Company has a legal or constructive obligation at the balance sheet date as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation.

Provisions are measured at net realisable value or at fair value if the obligation is expected to be settled far into the future.

Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

Financial statements 1 January - 31 December

Notes to the financial statements

1 Accounting policies (continued)

Liabilities

The Company has chosen IAS 39 as interpretation for liabilities.

Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.

Other liabilities are measured at net realisable value.

Fair value

The fair value measurement is based on the principal market. If no principal market exists, the measurement is based on the most advantageous market, i.e. the market that maximises the price of the asset or liability less transaction and/or transport costs.

All assets and liabilities which are measured at fair value, or whose fair value is disclosed, are classified based on the fair value hierarchy, see below:

Level 1: Value in an active market for similar assets/liabilities

Level 2: Value based on recognised valuation methods on the basis of observable market information

Level 3: Value based on recognised valuation methods and reasonable estimates (non-observable market information).

If a reliable fair value cannot be stated according to the above levels, the asset or liability is measured at cost.

Financial statements 1 January - 31 December

Notes to the financial statements

DKK	<u>2024</u>	<u>2023</u>	
2 Staff costs			
Wages/salaries	598,657	250,450	
Other social security costs	4,566	4,593	
	<u>603,223</u>	<u>255,043</u>	
Average number of full-time employees	<u>1</u>	<u>1</u>	
3 Tax for the year			
Estimated tax charge for the year	83,695	238,964	
Deferred tax adjustments in the year	-10,942	-7,700	
	<u>72,753</u>	<u>231,264</u>	
4 Property, plant and equipment		Fixtures and fittings, other plant and equipment	
DKK		<u></u>	
Cost at 1 January 2024		158,000	
Cost at 31 December 2024		<u>158,000</u>	
Impairment losses and depreciation at 1 January 2024		87,777	
Depreciation		<u>52,666</u>	
Impairment losses and depreciation at 31 December 2024		<u>140,443</u>	
Carrying amount at 31 December 2024		<u>17,557</u>	
Depreciated over		<u>3-5 years</u>	
5 Investments			
DKK	<u>Other receivables</u>	<u>Deposits, investments</u>	<u>Total</u>
Cost at 1 January 2024	3,681,446	31,438	3,712,884
Additions	549,952	1,270	551,222
Disposals	-1,044,584	0	-1,044,584
Cost at 31 December 2024	<u>3,186,814</u>	<u>32,708</u>	<u>3,219,522</u>
Carrying amount at 31 December 2024	<u>3,186,814</u>	<u>32,708</u>	<u>3,219,522</u>

Financial statements 1 January - 31 December

Notes to the financial statements

6 Cash

Client funds entrusted to the Company (klienttilsvar), DKK 147.689, are offset against cash.

7 Derivative financial instruments

Fair value disclosures

The Company has the following assets and liabilities measured at fair value:

DKK	Andre værdipapirer og kapitalandele, omsætnings akti ver
Fair value at year end	1,474,297
Unrealised fair value adjustments for the year, recognised in the income statement	-336,060
Fair value level	1

8 Contractual obligations and contingencies, etc.

Other financial obligations

Other rent and lease liabilities:

DKK	2024	2023
Rent and lease liabilities	32,708	32,067

9 Security and collateral

The Company has not provided any security or other collateral in assets at 31 December 2024.

The Company has entrusted client funds (klienttilsvar), which are offset in the Company's cash accounts. Please refer to note 7.

PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift. Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

Jan Bjerrum Bach

Direktion

På vegne af: Jusmedico Advokatanpartsselskab
Serienummer: 4a6fde23-0fb0-4f75-a9cb-a9a588227a6e
IP: 2.106.xxx.xxx
2025-06-27 14:43:02 UTC



Jan Bjerrum Bach

Dirigent

På vegne af: Jusmedico Advokatanpartsselskab
Serienummer: 4a6fde23-0fb0-4f75-a9cb-a9a588227a6e
IP: 2.106.xxx.xxx
2025-06-27 14:43:02 UTC



Robert Christensen

EY Godkendt Revisionspartnerselskab CVR: 30700228

Statsautoriseret revisor

På vegne af: EY Godkendt Revisionspartnerselskab
Serienummer: b24f52f4-2766-4b2f-9d6f-145e8a747b74
IP: 147.161.xxx.xxx
2025-06-27 15:18:05 UTC



Dette dokument er underskrevet digitalt via [Penneo.com](https://penneo.com). De underskrevne data er valideret vha. den matematiske hashværdi af det originale dokument. Alle kryptografiske beviser er indlejret i denne PDF for validering i fremtiden.

Dette dokument er forseglet med et kvalificeret elektronisk segl. For mere information om Penneos kvalificerede tillidstjenester, se <https://eutl.penneo.com>.

Sådan kan du verificere, at dokumentet er originalt
Når du åbner dokumentet i Adobe Reader, kan du se, at det er certificeret af **Penneo A/S**. Dette beviser, at indholdet af dokumentet er uændret siden underskriftstidspunktet. Bevis for de individuelle underskrivers digitale underskrifter er vedhæftet dokumentet.

Du kan verificere de kryptografiske beviser vha. Penneos validator, <https://penneo.com/validator>, eller andre valideringstjenester for digitale underskrifter.